×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Canagliflozin does not increase risk of below- knee amputation in people with type 2 diabetes

  890 Views

eMediNexus    01 July 2018

Canagliflozin does not increase the risk of amputation for the general type 2 diabetes population or in patients with established cardiovascular disease, but does reduce a patient’s risk of hospitalization for heart failure, according to a study presented June 24, 2018 at the 78th Scientific Session of the ADA in Orlando, Florida.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.